Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification

Human Pathology

Volumn 41, Issue 11, 2010, Pages 1617-1623

  Vranic, Semir ^a,b   Frkovic Grazio, Snjezana ^c   Lamovec, Janez ^c   Serdarevic, Fadila ^a   Gurjeva, Olga ^d   Palazzo, Juan ^e   Bilalovic, Nurija ^a   Lee, Lisa M J ^b   Gatalica, Zoran ^b  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d Emergency Cardiology Department   (Ukraine)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Adenoid cystic carcinoma; Breast carcinoma; Outcome; Predictive markers

Indexed keywords

ANDROGEN RECEPTOR; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; EGFR PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; ADENOID CYSTIC CARCINOMA; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; MASTECTOMY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS, MALE; CARCINOMA, ADENOID CYSTIC; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MASTECTOMY; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; DNA TOPOISOMERASES, TYPE II;

EID: 77957947579     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.04.013     Document Type: Article

References (53)

1. Millar B.A., Kerba M., Youngson B., Lockwood G.A., and Liu F.F. The potential role of breast conservation surgery and adjuvant breast radiation for adenoid cystic carcinoma of the breast Breast Cancer Res Treat 87 2004 225 232
2. Azoulay S., Laé M., and Fréneaux P. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome Mod Pathol 18 2005 1623 1631
3. Mastropasqua M.G., Maiorano E., and Pruneri G. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast Mod Pathol 18 2005 1277 1282
4. Magkou C., Nakopoulou L., and Zoubouli C. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas Breast Cancer Res 10 2008 R49
5. Viale G., Rotmensz N., and Maisonneuve P. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity Breast Cancer Res Treat 116 2009 317 328
6. Rakha E.A., Putti T.C., and Abd El-Rehim D.M. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation J Pathol 208 2006 495 506
7. Harari P.M., Allen G.W., and Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents J Clin Oncol 25 2007 4057 4065
8. Nielsen K.V., Ejlertsen B., and Møller S. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D Acta Oncol 47 2008 725 734
9. Celis J.E., Cabezon T., and Moreira J.M. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort Mol Oncol 3 2009 220 237
10. Honma N., Sakamoto G., and Akiyama F. Breast carcinoma in women over the age of 85: distinct histological pattern an androgen, oestrogen, and progesterone receptor status Histopathology 42 2003 120 127
11. Fritz P., Cabrera C.M., and Dippon J. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study Breast Cancer Res 7 2005 R374 R384
12. Sandri M.I., Hochhauser D., and Ayton P. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers Br J Cancer 73 1996 1518 1524
13. Wolff A.C., Hammond M.E., and Schwartz J.N. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
14. O'Malley F.P., Chia S., and Tu D. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 2009 644 650
15. Vanden Bempt I., Van Loo P., and Drijkoningen M. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 2008 4869 4874
16. Krishnamurti U., Hammers J.L., Atem F.D., Storto P.D., and Silverman J.F. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma Mod Pathol 22 2009 1044 1048
17. World Health Organization Classification of Tumours F.A. Tavassoli, P. Devilee, Pathology and genetics of tumours of the breast and female genital organs 2003 IARC Press Lyon, France 44 45
18. Kasami M., Olson S.J., Simpson J.F., and Page D.L. Maintenance of polarity and a dual cell population in adenoid cystic carcinoma of the breast: an immunohistochemical study Histopathology 32 1998 232 238
19. Kleer C.G., and Oberman H.A. Adenoid cystic carcinoma of the breast: value of histologic grading and proliferative activity Am J Surg Pathol 22 1998 569 575
20. Shin S.J., and Rosen P.P. Solid variant of mammary adenoid cystic carcinoma with basaloid features. A study of nine cases Am J Surg Pathol 26 2002 413 420
21. Weigelt B., Horlings H.M., and Kreike B. Refinement of breast cancer classification by molecular characterization of histological special types J Pathol 216 2008 141 150
22. Page D.L. Adenoid cystic carcinoma of breast, a special histopathologic type with excellent prognosis Breast Cancer Res Treat 93 2005 189 190
23. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options Lancet Oncol 8 2007 235 244
24. Sarnaik A.A., Meade T., and King J. Adenoid Cystic Carcinoma of the Breast: A Review of a Single Institution's Experience Breast J 2009 [Epub ahead of print]
25. Soon S.R., Yong W.S., Ho G.H., Wong C.Y., Ho B.C., and Tan P.H. Adenoid cystic breast carcinoma: a salivary gland-type tumour with excellent prognosis and implications for management Pathology 40 2008 413 415
26. Arpino G., Clark G.M., Mohsin S., Bardou V.J., and Elledge R.M. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome Cancer 94 2002 2119 2127
27. Peters G.N., and Wolff M. Adenoid cystic carcinoma of the breast. Report of 11 new cases: review of the literature and discussion of biological behavior Cancer 52 1983 680 686
28. Vranic S., Bilalovic N., Lee L.M., Kruslin B., Lilleberg S.L., and Gatalica Z. PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney Hum Pathol 38 2007 1425 1431
29. Aleskandarany M.A., Rakha E.A., and Ahmed M.A. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis Breast Cancer Res Treat 2009 [Epub ahead of print]
30. Sinn H.P., Lehnert T., and Otto H.F. Adenoid cystic cancer of the breast. Case report and meta-analysis of the literature Chirurg 64 1993 198 202
31. McClenathan J.H., and de la Roza G. Adenoid cystic breast cancer Am J Surg 183 2002 646 649
32. Leeming R., Jenkins M., and Mendelsohn G. Adenoid cystic carcinoma of the breast Arch Surg 127 1992 233 235
33. Crabb S.J., Cheang M.C., and Leung S. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer Clin Breast Cancer 8 2008 249 256
34. Schneider B.P., Winer E.P., and Foulkes W.D. Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 2008 8010 8018
35. Rydén L., Jirström K., Haglund M., Stål O., and Fernö M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up Breast Cancer Res Treat 120 2010 490 498
36. Nielsen T.O., Hsu F.D., and Jensen K. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
37. Matte C., Gilbert J.A., and Blair H.A. Molecular analysis of KIT and epidermal growth factor receptor in adenoid cystic carcinoma of the breast Mod Pathol 21 Suppl. 1 2008 46A [abstract]
38. Defaud-Hénon F., Tunon-de-Lara C., and Fournier M. Adenoid cystic carcinoma of the breast: clinical, histological and immunohistochemical characterization Ann Pathol 30 2010 7 16
39. Bhargava R., Gerald W.L., and Li A.R. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGF-activating mutations Mod Pathol 18 2005 1027 1033
40. Cho E.Y., Choi Y.L., Han J.J., Kim K.M., and Oh Y.L. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization Pathol Int 58 2008 17 25
41. Modjtahedi H., and Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities Anticancer Drugs 20 2009 851 855
42. Hoadley K.A., Weigman V.J., and Fan C. EGFR associated expression profiles vary with breast tumor subtype BMC Genomics 8 2007 258
43. Di Leo A., Biganzoli L., Claudino W., Licitra S., Pestrin M., and Larsimont D. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer 44 2008 2791 2798
44. Tanner M., Isola J., and Wiklund T. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 2006 2428 2436
45. Gennari A., Sormani M.P., and Pronzato P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 2008 14 20
46. Tan D.S., Marchió C., and Jones R.L. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat 111 2008 27 44
47. Trendell-Smith N.J., Peston D., and Shousha S. Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins Histopathology 35 1999 241 248
48. Crisi G.M., Marconi S., Makari-Judson G., and Goulart R.A. Expression of c-kit in adenoid cystic carcinoma of the breast Am J Clin Pathol 124 2005 733 739
49. Isola J.J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors J Pathol 170 1993 31 35
50. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ Pathol Res Pract 193 1997 753 758
51. Park S., Koo J., and Park H.S. Expression of androgen receptors in primary breast cancer Ann Oncol 21 2010 488 492
52. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., and Ellis I.O. Prognostic markers in triple-negative breast cancer Cancer 109 2007 25 32
53. Laurent-Puig P., Lievre A., and Blons H. Mutations and response to epidermal growth factor receptor inhibitors Clin Cancer Res 15 2009 1133 1139